Search company, investor...

Callisto Pharmaceuticals

Founded Year



Acquired | Acquired

Total Raised


About Callisto Pharmaceuticals

Callisto Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat multiple myeloma (an incurable blood cancer that invades and proliferates in bone marrow), and osteolytic bone disease, among other cancers. The Company's lead drug candidate, Atiprimod, is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity. The Company was formed, in April 2003, through a reverse acquisition between Callisto Pharmaceuticals and Webtronics.In January 2013, Callisto Pharmaceuticals was acquired by Synergy Pharmaceuticals. The valuation of Callisto Pharmaceuticals was undisclosed. Other terms of the deal were not released.

Headquarters Location

420 Lexington Avenue Suite 1609

New York, New York, 10170,

United States


Missing: Callisto Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Callisto Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Callisto Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Callisto Pharmaceuticals is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Latest Callisto Pharmaceuticals News

OKYO Pharma Limited: Directorate Change

Dec 1, 2021

A Bernard F. Denoyer (age: 74) Bernard F. Denoyer has 49 years of financial management experience including his service as Senior Vice President, Finance and Secretary of development stage Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) from July 2008 until FDA approval and his retirement in June 2017. Mr. Denoyer concurrently served as Principal Financial Officer of Synergy’s former parent company, Callisto Pharmaceuticals, Inc. While with SGYP and CLSP he supported over $500M of public and PIPE financings with related due diligence, SEC registrations and market listings. From October 2000 to December 2003, Mr. Denoyer was an independent consultant, providing interim CFO and other services to emerging businesses, including Callisto and certain portfolio companies of Marsh & McLennan Capital, LLC. From October 1994 until September 2000, Mr. Denoyer served as Chief Financial Officer and Senior Vice President of META Group, Inc., an information technology research company. Mr. Denoyer earned his CPA with Ernst & Young in 1975. He received a Masters Certificate of Accounting from the Kellogg Graduate School of Management in 1974, an MBA in Finance with honors from Columbia Business School in 1972, and a BA in Economics from Fairfield University in 1969. Mr. Denoyer is fluent in French and studied in Paris at l’Istitut d’Etude Politique et Economique in 1968. He served in U.S. Army in Vietnam from 1969 to 1971 and has been an adjunct accounting professor at Fairfield University and the Marymount College. He is currently serving on the Board of Trustees for two 501(c)3 not-for-profits, St. Edmunds Retreat, Inc. and Midwestern Connecticut Council on Alcoholism, Inc. Mr Denoyer will assume the role chair the Nomination Committee of the Board from Mr Gabriele Cerrone (who will continue to serve as a member of the Nomination Committee). With immediate effect Willy Simon will assume the role of senior non-executive and will continue to chair the Remuneration Committee of the Board. Gabriele Cerrone, Chairman of OKYO, said, "We are delighted that Bernard has joined the Board of OKYO. His expertise will be of great value to us at a very important time for the group." There are no other disclosures to make pursuant to Listing Rule 9.6.13, in respect of Mr Denoyer's appointment. The person who approved the content of this announcement for purposes of UK MAR was Dr Gary Jacob, Chief Executive Officer. About OKYO OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Enquiries:

Callisto Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Callisto Pharmaceuticals founded?

    Callisto Pharmaceuticals was founded in 1996.

  • Where is Callisto Pharmaceuticals's headquarters?

    Callisto Pharmaceuticals's headquarters is located at 420 Lexington Avenue, New York.

  • What is Callisto Pharmaceuticals's latest funding round?

    Callisto Pharmaceuticals's latest funding round is Acquired.

  • How much did Callisto Pharmaceuticals raise?

    Callisto Pharmaceuticals raised a total of $4.84M.

  • Who are the investors of Callisto Pharmaceuticals?

    Investors of Callisto Pharmaceuticals include Synergy Pharmaceuticals, New England Partners, Ashton Partners, Anima S.G.R.p.A, Banque Profil de Gestion S.A. and 21 more.

  • Who are Callisto Pharmaceuticals's competitors?

    Competitors of Callisto Pharmaceuticals include Sierra Oncology, Sound Pharmaceuticals, Longevica, Portola Pharmaceuticals, Innate Pharma and 14 more.

Compare Callisto Pharmaceuticals to Competitors

Philogen Logo

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of biopharmaceutical products. Philogen's strategy is to deliver bioactive agents, for example cytokines or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. This technology has generated a strong pipeline of clinical-stage products and also pre-clinical compounds in an array of disease indications.

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.


Oraceuticals uses biotechnologies to develop drugs that advance oral treatment and improve oral health. Focuses on producing bioactive molecules that target chronic oral infections and control inflammation.


Argenes, Inc. is a Japanese bio-venture established in April 2004 focusing primarily on the development of biopharmaceuticals and molecular targeting therapeutics, including anti-rheumatoid arthritis (RA), and anti-osteoarthritis. Currently, the company's most innovatory prospective candidate for the treatment of RA is the drug anti-Fas mAb ARG098. The company operate preclinical and clinical studies as well as manufacturer pharmaceuticals through managing of CRO and CMO. At Argenes, Inc. the company continually seek to expand globally through creating alliances and through licensing out development rights and marketing rights.

Sound Pharmaceuticals

Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.


Founded in 2005 Ora Bio Ltd, a biopharmaceutical company, is engaged in the repositioning of existing drugs for second-use applications. nnThe Company is developing its two products, the ORA101 and ORA102, as drugs for non-small cell lung cancer (NSCLC) and age-related macular degeneration (AMD) respectively. Both the company's products are currently in Phase II clinical trials.n

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.